Healthcare Industry News:  Acute Coronary Syndrome 

Devices Interventional Cardiology

 News Release - March 12, 2009

Acute myocardial infarction (AMI) successfully treated with Stentys self-expanding platform, solving stent-malapposition

“These first two AMI patients demonstrated not only perfect acute stent apposition with no balloon-induced vessel trauma but also identical apposition after 0.3mm vessel expansion five days later,” said Gonzague Issenmann, CEO of Stentys.

PARIS--(HSMN NewsFeed)--Medical device pioneer Stentys announced today that it has extended its ‘self-expanding’ and ‘disconnectable’ technology platform to include a second major indication—acute myocardial infarction (AMI). Two patients were successfully treated during acute myocardial infarction procedures last week by Drs. S. Verheye (Antwerp, Belgium) and K. E. Hauptmann (Trier, Germany).

The versatile Stentys platform has two features— self-expansion and disconnectability—that are designed to be unrivaled in the stent industry. The self-expanding feature insures optimal apposition in the critical initial hours and days after the procedure by being constantly applied to the vessel surface during thrombus and vessel spasm relief, therefore avoiding malapposition, a significant concern to cardiologists. The disconnectability feature is designed to treat lesions close to a bifurcation, by ensuring safe main branch provisional stenting and optimal side branch access when needed. Equally important, the Stentys platform is implanted by usual stenting techniques requiring no additional training.

“The Stentys device was simple to implant, conformed snugly to the treated vessel, and created minimal vessel injury since no high-pressure inflation was required,” said Dr. Verheye. “When comparing immediate and five days post-procedure results using IVUS (intravascular ultrasound), the coronary vessel expanded slightly, and Stentys followed intimately the vessel remodeling with perfect apposition.”

“We are extremely pleased with these preliminary results which suggest that AMI patients may be better treated. This adds a second indication to the Stentys self-expandable platform and consequently doubles the Company’s market opportunities,” added Jacques Séguin, M.D., Ph.D., Chairman of Stentys.

About Stentys

Based in Paris, France, and Princeton, N.J., Stentys, a privately held company, has developed a self-expanding platform aimed at enhancing the treatment of complex coronary lesions such as Acute Coronary Syndromes or lesions close to coronary bifurcations.


Source: Stentys

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.